STOCK TITAN

Aldeyra Therapeutics Inc - ALDX STOCK NEWS

Welcome to our dedicated news page for Aldeyra Therapeutics (Ticker: ALDX), a resource for investors and traders seeking the latest updates and insights on Aldeyra Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aldeyra Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aldeyra Therapeutics's position in the market.

Rhea-AI Summary
Aldeyra Therapeutics, Inc. (ALDX) announced that its CEO will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The virtual conference will take place on February 13-14, 2024. The conversation will be available for live webcast and archived for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.05%
Tags
conferences
-
Rhea-AI Summary
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announces advancement of its RASP modulator platform, including the expected submission to the FDA of a proposed expansion of the Phase 2 clinical trial of the investigational RASP modulator ADX-629 in Sjögren-Larsson Syndrome to include pediatric patients, initiation of a Phase 2 clinical trial of ADX-629 in moderate alcoholic hepatitis, and submission of IND applications for ADX-246 and ADX-248 for clinical trials in atopic dermatitis and dry age-related macular degeneration patients, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
none
-
Rhea-AI Summary
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced positive top-line results from a Phase 2 clinical trial of ADX-629, an investigational RASP modulator, in patients with atopic dermatitis. The trial demonstrated statistically significant improvement in EASI, IGA, HAM-D, and POEM scores, with complete resolution of affected body surface area observed in one patient. The company plans to advance ADX-246, a next-generation investigational RASP modulator, to Phase 1/2 clinical testing in healthy volunteers and atopic dermatitis patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.58%
Tags
clinical trial
Rhea-AI Summary
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced a webcast and conference call to provide top-line results from a Phase 2 clinical trial of ADX‑629 in patients with atopic dermatitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.58%
Tags
clinical trial
-
Rhea-AI Summary
Aldeyra Therapeutics, Inc. (ALDX) receives a Complete Response Letter from the FDA for reproxalap, an investigational drug candidate for dry eye disease. The FDA states that the NDA did not demonstrate efficacy in treating ocular symptoms associated with dry eyes, requiring an additional trial. Aldeyra submitted a Special Protocol Assessment for a dry eye disease chamber crossover clinical trial, with top-line results anticipated in the first half of 2024. The potential NDA resubmission is also expected in the first half of 2024. Aldeyra plans to extend its cash runway into late 2025, with $143 million in cash, cash equivalents, and marketable securities as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.05%
Tags
none
-
Rhea-AI Summary
Aldeyra Therapeutics has entered into an exclusive option agreement with AbbVie Inc. The agreement grants AbbVie the option to acquire a co-exclusive license to develop, manufacture, and commercialize reproxalap in the U.S. and an exclusive license to do the same outside the U.S. Aldeyra will receive a $1 million non-refundable option fee and a $100 million upfront payment if AbbVie exercises the option. Aldeyra could also receive up to $300 million in regulatory and commercial milestone payments. The terms of the license agreement include profit and loss sharing between Aldeyra and AbbVie, with a 60% split for AbbVie and 40% for Aldeyra in the U.S. market. Aldeyra would also be eligible for tiered royalties on net sales of reproxalap outside the U.S. AbbVie will have the right of first negotiation for compounds owned or controlled by Aldeyra in the field of ophthalmology relating to treating conditions of the ocular surface.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
48.54%
Tags
none
Rhea-AI Summary
A lawsuit has been filed against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) by investors alleging violations of securities laws. The lawsuit claims that the company made false and misleading statements regarding the effectiveness of ADX-2191. Investors who purchased over $100,000 worth of ALDX shares between March 2022 and June 2023 should contact the Shareholders Foundation, Inc. Deadline for action is September 29, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
conferences
-
Rhea-AI Summary
Aldeyra Therapeutics announces positive results from Phase 2 clinical trial of ADX-2191 for retinitis pigmentosa
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
clinical trial
Aldeyra Therapeutics Inc

Nasdaq:ALDX

ALDX Rankings

ALDX Stock Data

163.73M
43.34M
2.01%
60.62%
3.28%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Lexington

About ALDX

dedicated to improving lives by developing products that treat aldehyde-mediated diseases. we are a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. we are developing adx-102 (formerly ns2), as well as other novel product candidates that are designed specifically to sequester aldehydes, for the treatment of: • noninfectious anterior uveitis, a rare severe inflammatory eye disease that can lead to blindness; • allergic conjunctivitis, a common disease that affects more than 20% of the population worldwide, and related rare allergic ocular diseases that are characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, swelling, and redness; • dry eye disease, a common inflammatory dise